Related Experiment Video

Updated: May 10, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K

Pediatric onset multiple sclerosis in Kuwait

Raed Alroughani1, Malak AlMojel2, Dalal Qasem2

  • 1Division of Neurology, Amiri Hospital, Arabian Gulf Street, Sharq 13041, Kuwait.

Clinical Neurology and Neurosurgery
|November 23, 2024
PubMed

Insights

Pediatric-onset multiple sclerosis (POMS) in Kuwait predominantly affects females and often presents with brainstem/cerebellar symptoms. Many POMS patients maintain a relapsing phenotype, with disease breakthrough common on platform therapies.

Area of Science:

  • Neurology
  • Immunology
  • Pediatrics

Background:

  • Limited epidemiological data exists for pediatric-onset multiple sclerosis (POMS) in the Middle East.
  • Understanding POMS characteristics is crucial for effective management in this region.

Purpose of the Study:

  • To investigate the demographic and clinical features of POMS in Kuwait.
  • To provide insights into disease presentation, phenotype, and treatment response in a Middle Eastern cohort.

Main Methods:

  • Retrospective study of 249 patients with POMS (onset < 18 years) meeting International Pediatric MS Study Group criteria.
  • Analysis of demographic data, clinical presentation, disease phenotype, and treatment history.

Main Results:

  • 70.3% of POMS patients were female, with a mean age at onset of 15.06 years.
  • Brainstem/cerebellar (34.9%), spinal (29.3%), and visual pathway (27.3%) symptoms were common initial presentations.
  • 83.5% maintained a relapsing-remitting phenotype; 36.1% experienced disease breakthrough on platform therapies.

Conclusions:

  • POMS in Kuwait primarily affects females and often presents with neurological symptoms affecting the brainstem, cerebellum, or spinal cord.
  • The majority of POMS patients exhibit a relapsing-remitting course, and disease breakthrough is a frequent challenge, particularly with initial platform therapies.
Abstract

Keywords:
EpidemiologyKuwaitPediatric multiple sclerosis

More Related Videos

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.5K
Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE06:04

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Published on: August 16, 2024

752

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...